Multiple Myeloma: Inside the Issue of Cereblon E3 Ligase Modulators
About this episode
Dr Natalie S Callander and Dr Paul G Richardson discuss the role of CELMoDs in managing multiple myeloma.
Dr Natalie S Callander from the University of Wisconsin Carbone Cancer Center in Madison and Dr Paul G Richardson from Dana-Farber Cancer Institute in Boston, Massachusetts, discuss the potential role of CELMoDs in the management of multiple myeloma, supporting clinical data and ongoing investigations. CME information and select publications here .
More episodes of Hematologic Oncology Update
- Acute Myeloid Leukemia — Year in Review Series on Relevant New Datasets and Advances
- CELMoDs for Multiple Myeloma — Microlearning Activity 2 with Dr Paul G Richardson
- Immune Thrombocytopenia — Microlearning Activity 4 with Dr Hanny Al-Samkari: ASH 2025 Review
- CELMoDs for Multiple Myeloma — Microlearning Activity 1 with Dr Paul G Richardson
- Immune Thrombocytopenia — Microlearning Activity 3 with Dr Hanny Al-Samkari: ASH 2025 Review
- CD19 x CD3 BiTEs for Acute Lymphoblastic Leukemia — An Interview with Dr Bijal Shah
Explore listener stats, chart rankings, contacts and more on the Hematologic Oncology Update podcast page.